Kwang Dong Pharmaceutical Co., Ltd.

KOSE:A009290 Rapporto sulle azioni

Cap. di mercato: ₩257.7b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kwang Dong Pharmaceutical Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Kwang Dong Pharmaceutical.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili38.3%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

None

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding

Aug 06
There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding

Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals

Mar 25
Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals

Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking

Mar 20
Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking

Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?

Apr 29
Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?

Is Now The Time To Put Kwang Dong Pharmaceutical (KRX:009290) On Your Watchlist?

Apr 06
Is Now The Time To Put Kwang Dong Pharmaceutical (KRX:009290) On Your Watchlist?

Did Business Growth Power Kwang Dong Pharmaceutical's (KRX:009290) Share Price Gain of 117%?

Mar 18
Did Business Growth Power Kwang Dong Pharmaceutical's (KRX:009290) Share Price Gain of 117%?

Is Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Popular Amongst Insiders?

Mar 01
Is Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Popular Amongst Insiders?

Should Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Be Part Of Your Dividend Portfolio?

Feb 14
Should Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Be Part Of Your Dividend Portfolio?

Estimating The Fair Value Of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)

Feb 01
Estimating The Fair Value Of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)

Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly

Jan 19
Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly

If You Like EPS Growth Then Check Out Kwang Dong Pharmaceutical (KRX:009290) Before It's Too Late

Jan 06
If You Like EPS Growth Then Check Out Kwang Dong Pharmaceutical (KRX:009290) Before It's Too Late

Here's What We Like About Kwang Dong Pharmaceutical's (KRX:009290) Upcoming Dividend

Dec 24
Here's What We Like About Kwang Dong Pharmaceutical's (KRX:009290) Upcoming Dividend

Can You Imagine How Kwang Dong Pharmaceutical's (KRX:009290) Shareholders Feel About The 54% Share Price Increase?

Dec 18
Can You Imagine How Kwang Dong Pharmaceutical's (KRX:009290) Shareholders Feel About The 54% Share Price Increase?

Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?

Dec 04
Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?

What Type Of Shareholders Own The Most Number of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Shares?

Nov 21
What Type Of Shareholders Own The Most Number of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Shares?

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Kwang Dong Pharmaceutical non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

KOSE:A009290 - Stime future degli analisti e dati finanziari passati (KRW Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
3/31/20241,569,99141,121-69,045-30,777N/A
12/31/20231,514,45436,966-46,847-11,730N/A
9/30/20231,509,98138,578-22,58810,478N/A
6/30/20231,489,79336,18925,91053,359N/A
3/31/20231,476,24830,63133,95863,056N/A
12/31/20221,431,54524,17436,82262,822N/A
9/30/20221,412,47823,61554,47475,661N/A
6/30/20221,385,26426,11553,44674,132N/A
3/31/20221,356,28725,45340,21853,212N/A
12/31/20211,338,18224,01930,49354,940N/A
9/30/20211,282,05610,64219,31539,579N/A
6/30/20211,247,49632,216-1,51917,526N/A
3/31/20211,237,24040,840-45817,158N/A
12/31/20201,243,77045,37017,52522,829N/A
9/30/20201,256,38854,62126,57932,602N/A
6/30/20201,244,06428,20342,83850,938N/A
3/31/20201,244,96324,62730,12242,473N/A
12/31/20191,238,25523,05816,60329,285N/A
9/30/20191,215,66722,30416,81433,343N/A
6/30/20191,224,38626,756-3,63012,512N/A
3/31/20191,198,93924,20014,01327,949N/A
12/31/20181,180,22022,34533,95253,096N/A
9/30/20181,163,67323,47114,52330,255N/A
6/30/20181,148,40225,1698,07028,272N/A
3/31/20181,152,53324,15316,19136,081N/A
12/31/20171,141,56623,196N/A23,465N/A
9/30/20171,128,69322,482N/A7,231N/A
6/30/20171,100,13720,602N/A17,761N/A
3/31/20171,076,30626,392N/A16,423N/A
12/31/20161,056,42928,063N/A28,799N/A
9/30/20161,066,94431,922N/A49,903N/A
6/30/20161,076,68133,587N/A43,207N/A
3/31/20161,077,61735,062N/A43,562N/A
12/31/2015955,45435,015N/A41,139N/A
9/30/2015808,36336,695N/A40,391N/A
6/30/2015674,91337,955N/A43,160N/A
3/31/2015533,99936,215N/A37,383N/A
12/31/2014522,27435,044N/A32,750N/A
9/30/2014508,92332,721N/A33,515N/A
6/30/2014497,11131,688N/A41,335N/A
3/31/2014479,96523,047N/A37,239N/A
12/31/2013468,38522,037N/A34,394N/A
9/30/2013436,42323,110N/A39,150N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if A009290's forecast earnings growth is above the savings rate (2.6%).

Guadagni vs Mercato: Insufficient data to determine if A009290's earnings are forecast to grow faster than the KR market

Guadagni ad alta crescita: Insufficient data to determine if A009290's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if A009290's revenue is forecast to grow faster than the KR market.

Ricavi ad alta crescita: Insufficient data to determine if A009290's revenue is forecast to grow faster than 20% per year.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if A009290's Return on Equity is forecast to be high in 3 years time


Scoprire le aziende in crescita